Trials, therapies, and evidence that changes care.
Europe PMC
Verdict: MajorBackground Orforglipron is an oral, non-peptide GLP-1 receptor agonist.
Safiglipron is an oral small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist administered without fasting or dietary restrictions.
Background Hypofractionated radiotherapy is an established alternative to conventional fractionation for breast cancer, but long-term evidence after mastectomy with regional nodal irradiation is scarce.
Background Complement-dependent cytotoxicity (CDC) of CD38 monoclonal antibodies has been associated with infusion-related reactions and might contribute to reduced clinical efficacy of CDC-reliant CD38 antibodies…
Background For persons living with both type 2 diabetes and obesity, weight management may be the most effective therapy for type 2 diabetes.
Zabilugene almadenorepvec (VCN-01) is a hyaluronidase-expressing oncolytic adenovirus with a favorable safety profile and encouraging antitumor activity in patients with pancreatic ductal ....
Background Giredestrant and everolimus target the estrogen receptor (ER) pathway and the phosphatidylinositol 3-kinase (PI3K)-protein kinase B (AKT)-mammalian target of rapamycin (mTOR) ....